DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Efmoroctocog alfa
Efmoroctocog alfa
Australian Public Assessment for Efmoroctocog Alfa (Rhu)
Human and Recombinat Coagulation Factor VIII
PRESS RELEASE Stockholm, Sweden, 8 July 2020
Australian Public Assessment Report for Lonoctocog Alfa (Rch)
Justification
Dossier Zur Nutzenbewertung Gemäß § 35A SGB V
Utah Medicaid Pharmacy and Therapeutics Committee Drug Class Review
Stembook 2018.Pdf
Biopharmaceutical Benchmarks 2018
Recombinant Factor VIII: Past, Present and Future of Treatment of Hemophilia A
Hemophilia Treatment: Factors to Consider
(INN) for Biological and Biotechnological Substances
EHL FVIII Regimens for the Management of Hemophilia A
WFH Treatment Guidelines 3Ed Chapter 3 Laboratory
PRESSMEDDELANDE Stockholm, 6 November 2020
ELOCTA, INN-Efmoroctocog Alfa
February-March 2017
Monitoring International Trends
Top View
Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England
Illuminating the Role of Shared Decision-Making As the Hemophilia a Management Landscape Continues to Evolve: Progress in Practice
Essential List of Medicinal Products for Rare Diseases: Recommendations from the Irdirc Rare Disease Treatment Access Working Group William A
13, 2020 Individual
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review
Elocta, INN-Efmoroctocog Alfa
International Nonproprietary Names (INN) for Biological and Biotechnological Substances
Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
Minutes of the CHMP Meeting 20-23 July 2020
Modul 4 a Behandlung Und Prophylaxe Von Blutungen Bei Patien- Ten Mit Hämophilie A
Factor VIII Article-31
Focus on Rare Diseases Annual and Sustainability Report 2019
Prescription Medicines and Biologicals: TGA Annual Summary 2016 Prescription Medicines and Biologicals: TGA Annual Summary 2016 Contents
PRESS RELEASE Stockholm, Sweden, 6 November 2020
Sobi™ Publishes 2020 Annual and Sustainability Report
Report Template
CHMP Agenda of the 28-30 April 2020 Meeting
ELOCTA, INN-Efmoroctocog Alfa
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
CHMP Agenda of the 25-29 January 2021 Meeting
Review of Factor VIII Medicines Started
List of Medicinal Products Under Additional Monitoring
List Item Minutes of the COMP Meeting 6-8 October 2015 (PDF
Emerging Insights in the Treatment of Patients with Haemophilia A
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2021 Issue One
Nhs-England-Drugs-List-V14.1.Pdf
November 2020 Monitoring International Trends
PRESS RELEASE Stockholm, Sweden, 7 July 2021
PRAC Agenda 11-14 January 2021
Biopharmaceutical Benchmarks 2018
(Jivi®) En Hemofilia A
(INN) for Biological and Biotechnological Substances
Peerview .Com /QUN900 Ensuring the Rapid Recognition and Optimal
Final Minutes CHMP 10-13 December 2018 Publication
(CHMP) Draft Agenda for the Meeting on 28-31 May 2018
11Beffbcaff5d6995a07dec57393
Joint Formulary for Hull and East Riding of Yorkshire
PRAC Draft Agenda of Meeting 13-16 January 2020
Tenofovir Alafenamide
Novel Treatments in Haemophilia and Other Bleeding Disorders: a Periodic EHC Review 2020 Issue Two
2017/19 Pbr Excluded Drugs: Proposed GMMMG Advisory Position [Appendix 3]
Efmoroctocog Alfa – Benefit Assessment According to §35A Social Code Book V1
Feb 2018-Mar 2018 Monitoring International Trends (Pdf)
Pbr Excluded Drugs List
Justification
Eloctate (Efmoroctocog Alfa) (Rhu) Powder and Solvent for Solution for Injection
Nhs-England-Drugs-List-V13.Pdf
List of Medicinal Products Under Additional Monitoring
Orphan Medicinal Products with Marketing Authorisation
Peer Review File